In the first week of Bowel Cancer Awareness Month 2019, the University of Sydney officially opened the Kolling Institute node of their Sydney Mass Spectrometry core facility.
The facility was made possible with a significant financial gift of $500,000 from Bowel Cancer Australia, established to support the research of the Lawrence Penn Chair of Bowel Cancer Research, Professor Mark Molloy PhD and his research team.
Members of the Bowel Cancer Australia board and guests were in attendance, along with the Deputy Vice-Chancellor (Research), Professor Duncan Ivison and Core Facilities Director, Professor Simon Ringer presiding.
Profiling of 60 bowel adenoma polyps will be used to better define optimal colonoscopic surveillance intervals, thanks to a new research grant to the Lawrence Penn Chair of Bowel Cancer Research from the Medical Research Future Fund (Sydney Health Partners).
Funding from the Colorectal Surgical Society ANZ Foundation will support new research to improve our understanding of why some early stage bowel tumours metastasise to lymph nodes.
“This is important because patients with lymph node disease have worse prognosis and face more intense treatment than patients whose cancer remains within the bowel wall,” said Lawrence Penn Chair of Bowel Cancer Research Professor Mark Molloy.
A new grant secured by the Lawrence Penn Chair of Bowel Cancer Research laboratory from the Cancer Institute NSW will enable further investigation into the prognostic contribution of immune cell infiltration in rectal cancer.
When Lawrence Penn was diagnosed with bowel cancer in 1985, the five-year relative survival rate was just 47 percent and life expectancy for newly diagnosed bowel cancer patients with advanced disease was just five months.
But as Lawrence celebrated his 96th birthday in December 2018, the bowel cancer landscape was gratefully a very different one.